CN111166897A - Sonoweiwei compound contrast agent and application - Google Patents
Sonoweiwei compound contrast agent and application Download PDFInfo
- Publication number
- CN111166897A CN111166897A CN201911165846.XA CN201911165846A CN111166897A CN 111166897 A CN111166897 A CN 111166897A CN 201911165846 A CN201911165846 A CN 201911165846A CN 111166897 A CN111166897 A CN 111166897A
- Authority
- CN
- China
- Prior art keywords
- sononovacin
- contrast agent
- reflux
- solution
- gastroesophageal reflux
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002872 contrast media Substances 0.000 title claims abstract description 91
- 150000001875 compounds Chemical class 0.000 title claims abstract description 26
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims abstract description 73
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 41
- 210000002784 stomach Anatomy 0.000 claims abstract description 30
- 239000002131 composite material Substances 0.000 claims abstract description 24
- 238000002156 mixing Methods 0.000 claims abstract description 22
- 230000002496 gastric effect Effects 0.000 claims description 37
- 238000010992 reflux Methods 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 24
- 238000011161 development Methods 0.000 claims description 20
- 238000009835 boiling Methods 0.000 claims description 19
- 230000008569 process Effects 0.000 claims description 14
- 230000003187 abdominal effect Effects 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000000243 solution Substances 0.000 abstract description 43
- 210000003238 esophagus Anatomy 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 13
- 239000002504 physiological saline solution Substances 0.000 abstract description 6
- 210000005022 abdominal esophagus Anatomy 0.000 abstract description 5
- 230000029142 excretion Effects 0.000 abstract description 4
- 230000002349 favourable effect Effects 0.000 abstract description 4
- 231100000915 pathological change Toxicity 0.000 abstract description 3
- 230000036285 pathological change Effects 0.000 abstract description 3
- 238000002601 radiography Methods 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 2
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- 238000003745 diagnosis Methods 0.000 description 18
- 238000001514 detection method Methods 0.000 description 17
- 238000012360 testing method Methods 0.000 description 15
- 238000001816 cooling Methods 0.000 description 14
- 210000002318 cardia Anatomy 0.000 description 12
- 238000003384 imaging method Methods 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 238000002604 ultrasonography Methods 0.000 description 10
- 229910018503 SF6 Inorganic materials 0.000 description 9
- 208000000689 peptic esophagitis Diseases 0.000 description 9
- SFZCNBIFKDRMGX-UHFFFAOYSA-N sulfur hexafluoride Chemical compound FS(F)(F)(F)(F)F SFZCNBIFKDRMGX-UHFFFAOYSA-N 0.000 description 9
- 229960000909 sulfur hexafluoride Drugs 0.000 description 9
- 239000008213 purified water Substances 0.000 description 8
- 206010011985 Decubitus ulcer Diseases 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 206010067171 Regurgitation Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000002592 echocardiography Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 208000034991 Hiatal Hernia Diseases 0.000 description 3
- 206010020028 Hiatus hernia Diseases 0.000 description 3
- 206010030216 Oesophagitis Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 238000012805 post-processing Methods 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000012327 Endoscopic diagnosis Methods 0.000 description 2
- 206010019909 Hernia Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000001839 endoscopy Methods 0.000 description 2
- 208000006881 esophagitis Diseases 0.000 description 2
- 238000002608 intravascular ultrasound Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009967 tasteless effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- KEQXNNJHMWSZHK-UHFFFAOYSA-L 1,3,2,4$l^{2}-dioxathiaplumbetane 2,2-dioxide Chemical compound [Pb+2].[O-]S([O-])(=O)=O KEQXNNJHMWSZHK-UHFFFAOYSA-L 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 244000077995 Coix lacryma jobi Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 244000281702 Dioscorea villosa Species 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 208000014174 Oesophageal disease Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000005242 cardiac chamber Anatomy 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000002961 echo contrast media Substances 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 208000028299 esophageal disease Diseases 0.000 description 1
- 238000002580 esophageal motility study Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000004088 pulmonary circulation Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
Landscapes
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Acoustics & Sound (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention belongs to the technical field of ultrasonic examination, and particularly relates to a sononovacin compound contrast agent which is characterized by comprising 0.5-3ml of sononovacin solution and 500ml of water, wherein the sononovacin solution is prepared by mixing sononovacin 59mg and physiological saline 5 ml; and the application of sononovacin in preparing the composite contrast agent for detecting gastroesophageal reflux disease. The gas in the stomach and the esophagus can be eliminated in an ultrasonic radiography mode, the surrounding tissues are filtered for developing, the pathological changes in the abdominal esophagus and the stomach can be better displayed, and meanwhile, the slow excretion time is favorable for long-term careful observation of the condition of the stomach wall; and has no color, odor, toxicity, and side effects.
Description
Technical Field
The invention belongs to the technical field of ultrasonic examination, and particularly relates to a sononovacin composite contrast agent and application thereof.
Background
Gastroesophageal reflux disease (GERD) refers to symptoms and complications resulting from the regurgitation of stomach contents into the esophagus, mouth (including the larynx) or lungs. Gastroesophageal reflux disease is a dynamic disorder disease of the digestive tract caused by a plurality of factors, and the esophagus has the functions of defending gastric acid and the invasion of duodenal contents under the normal condition of esophagus reflux such as acid or other harmful substances such as monoacid, pancreatin and the like, and comprises a reflux-resistant barrier, an esophagus clearance function and the resistance of esophageal mucosal tissues. The onset of gastroesophageal reflux disease is a result of a decline in the defense mechanisms against reflux and the attacking effect of the reflux on the esophageal mucosa.
Gastroesophageal reflux not only causes damage to the digestive system but also affects the respiratory system, and the clinical symptoms are divided into esophageal symptoms and extraesophageal symptoms. It is manifested as discomfort, heartburn, epigastric pain, chest pain, dysphagia, chronic cough, asthma and other clinical symptoms, and is easy to cause esophageal mucosa erosion, ulcer, and even throat and trachea damage. Seriously affecting life and work. The disease incidence rate is about 10% -20% in foreign countries, about 5% -10% in China, and the disease incidence rate in China is on the rise at present. At present, detection methods such as 24-hour esophageal pH value detection, high-resolution esophageal manometry, acid induction test, nuclide gastroesophageal reflux examination, endoscopy and the like exist.
The detection of the pH value of the esophagus in 24 hours is the most accurate method for diagnosing the reflux esophagitis, the severity and the existence of complications of the reflux esophagitis can be judged by endoscopic examination, and the oesophagitis and other oesophageal diseases (such as oesophageal cancer and the like) caused by other reasons can be distinguished by combining biopsy. The diagnosis of gastroesophageal reflux disease can be established by endoscopic observation of reflux esophagitis, but gastroesophageal reflux disease cannot be excluded without reflux esophagitis. The esophageal 24-hour pH value monitoring is that a portable pH recorder is used for continuously monitoring the esophageal pH value of a patient for 24 hours under physiological conditions, can provide objective evidence for whether excessive W acid reflux exists in the esophagus, is recognized as an important diagnosis method for diagnosing gastroesophageal reflux disease at present, and has more important diagnosis value particularly when the symptoms of the patient are atypical, no reflux esophagitis exists and the treatment is ineffective although the symptoms are typical. Esophageal 24-hour pH monitoring is a diagnostic gold indicator. However, continuous monitoring of esophageal pH for 24 hours is expensive and takes a long time, and the patient suffers pain when the electrode catheter is inserted into the esophagus through one nasal cavity.
The X-ray examination of esophagus swallowing barium has certain effect, but has low sensitivity for diagnosing reflux esophagitis, and patients can be subjected to X-ray radiation, so that the examination is performed on the persons who are unwilling to accept or unable to tolerate endoscopy, and the aim of the X-ray examination is mainly to eliminate other esophagus diseases such as esophageal cancer. Heat of severe reflux esophagitis objectively finds positive X-ray signs.
Currently, the gastroesophageal reflux disease is observed in real time by utilizing the gastric development aid to examine under a two-dimensional ultrasonic state. The ultrasonic imaging aid can fill the gastrointestinal cavity quickly, produces a uniformly distributed interface with strong echoes similar to the echoes of parenchymal tissues (liver, kidney and pancreas) on an acoustic image, eliminates the interference of gas and mucus in the gastrointestinal cavity, generates obvious contrast effect between the gastrointestinal wall and the liver, gallbladder, spleen and pancreas, and clearly displays the hierarchy and structure of the gastrointestinal wall, thereby generating the best acoustic imaging effect for the gastrointestinal cavity. The basic components of the common gastrointestinal ultrasonic development aid are various traditional Chinese medicines which can reduce gas in the stomach, such as coix seeds, common yam rhizome, dried orange peel and the like, and the gastrointestinal ultrasonic development aid is rich in nutrition, good in taste and free of toxic and side effects. The ultrasonic mode has no pain of a common gastroscope, is not easy to cross-infect and does not need anesthesia. However, since the interference of the images of the surrounding tissues and the requirements for the technique and experience of the examiner are quite high, the examiner often makes erroneous judgment, and the missed diagnosis and the misdiagnosis are easy to occur.
Sonoweiwei (sulfur hexafluoride microvesicle for injection) is white powder, its main component is sulfur hexafluoride, and after the sulfur hexafluoride is added into the normal saline for injection it can be formed into milk white liquid, and when it is used in ultrasonic image, it can raise blood echo rate so as to raise signal-to-noise ratio. Sononovine is used for patients who cannot draw conclusions without contrast enhancement, such as echocardiography, large vessel doppler and small vessel doppler. Echocardiographic contrast of the pulmonary circulation may be used in echocardiography to enhance the opacity of the heart chamber when used in patients diagnosed with or suspected of having cardiovascular disease, thereby clearly delineating the left ventricular endocardial border line. The Doppler signal-to-noise ratio can be improved in the large vessel Doppler (examination), so that the accuracy of finding and removing diseases of cerebral arteries, extracranial carotid arteries or peripheral arteries is improved; can improve the Doppler imaging quality and prolong the clinically significant signal enhancement time in the portal vein aspect. Small vessel doppler (examination) sononoval enhances the visualization of liver and mammary lesion vascularization during doppler examination, and thus can be more accurately characterized.
The sononovine is injected into peripheral vein and enters blood vessel via vein to enhance back scattering echo, so as to improve resolution, sensitivity and specificity of ultrasonic diagnosis.
Disclosure of Invention
In order to solve the technical problems, the invention provides the sononovacin compound contrast agent and the application thereof, which can eliminate gas in the stomach and the esophagus in an ultrasonic contrast mode, filter out the surrounding tissues for developing, better display pathological changes in the stomach, delay the excretion time and be beneficial to observing the condition of the stomach wall carefully for a long time; and has no color, odor, toxicity, and side effects.
The sononovacin compound contrast agent in the invention for solving the technical problems is characterized in that: comprises 0.5-3ml of sononovacin solution and 300-600ml of water, wherein the sononovacin solution is prepared by dissolving 59mg of sononovacin in 5ml of normal saline.
2.5ml of sononovacin solution and 500-600ml of water; 500ml of water is used in the optimized scheme. Better filling of the stomach cavity, higher pressure, better examination effect and lower false negative rate.
The water is boiling water at 95-100 deg.C, and can be purified water. The boiling water is intended to be easily dissolved, homogeneous and non-demixing.
The composite contrast agent also comprises 50g of gastrointestinal development aid.
During the preparation process, the gastrointestinal development aid is first mixed with water to dissolve homogeneously, cooled to 37-40 deg.c, and then mixed with sononovalr solution to stir homogeneously. The reason for cooling is because high temperatures can destroy sononovacin microbubbles.
The sononovalue can be sulfur hexafluoride microvesicle for injection, and the gastric development aid can be gastrointestinal ultrasonic development aid, and is prepared from semen Armeniacae amarum, rhizoma Dioscoreae, pericarpium Citri Tangerinae, semen glycines and fructus Anisi Stellati, and is in the form of dark yellow granule with particle size of 12-50 meshes, and is dissolved in water.
The invention relates to a preparation method of a sononovacin compound contrast agent, which sequentially comprises a sononovacin solution blending step and a compound contrast agent blending step; or sequentially comprises a sononovalvynol solution blending step, a stomach development assistant blending step and a composite contrast agent blending step.
The sononovacin solution is prepared by dissolving sononovacin in physiological saline to obtain sononovacin solution.
The step of blending the gastric contrast aid comprises the steps of mixing and dissolving the gastrointestinal contrast aid and boiling water uniformly, and cooling to 37-40 ℃.
The step of blending the composite contrast agent is to uniformly mix the actually required dosage of the sononovacin solution with water and then cool the mixture to obtain the sononovacin contrast agent; or mixing the gastrointestinal development aid and boiling water, dissolving uniformly, cooling to 37-40 deg.C, adding the prepared Sonoweiwei solution, and stirring uniformly to obtain Sonoweiwei compound contrast agent.
The invention discloses an application of sononovacin compound contrast agent, which is an application of sononovacin in preparing compound contrast agent.
In the optimization scheme, the sononovacin is applied to preparation of the composite contrast agent for detecting gastroesophageal reflux disease.
The application mode in detecting the gastroesophageal reflux disease in the application is an oral mode.
The specific steps of the application of the invention in detecting gastroesophageal reflux disease are as follows:
(1) mixing with Sonoweiwei compound contrast medium;
(2) orally administering the cooled sononovacin complex contrast agent to a patient;
(3) according to the requirement of the checking body position, the patient is in a horizontal position or/and a right side position;
(4) dynamically observing and recording a concurrent image in real time; the real-time dynamic observation instrument is a high-end comprehensive color ultrasonic machine with an ultrasonic radiography function, and can observe, record and store images.
(5) Observing for 5-10min, if the reflux times are more than or equal to 3 times in the process, the gastroesophageal reflux can be diagnosed by the reflux time being more than or equal to 1s, or the process has reflux, but the reflux times and the reflux time are less than the standard, the physiological reflux can be diagnosed, namely, gastroesophageal reflux disease does not exist.
And a step of increasing abdominal pressure is also carried out between the step (4) and the step (5).
The method for checking body position and increasing abdominal pressure in the checking process is easier to be used for gastroesophageal reflux, and real-time dynamic image storage is more convenient for post-processing and analysis.
The composite contrast agent is colorless, tasteless, nontoxic and free of side effects, metabolism of a liver and kidney circulatory system is not performed, the time of microbubbles existing in the stomach is obviously prolonged compared with intravascular ultrasound contrast, and the gastroesophageal reflux condition can be observed conveniently. The scattering effect of the microbubbles after the vibration is favorable for observing the flowing condition of the contrast agent in the stomach and the esophagus, and the ultrasonic diagnosis specificity, sensitivity and diagnosis coincidence rate of the gastroesophageal reflux disease are improved. The gas in the stomach and the esophagus can be eliminated in the ultrasonic radiography mode, the surrounding tissues are filtered for developing, the lower esophagus and stomach lesions can be better displayed, and the slow excretion time in the stomach is favorable for long-term and careful observation of the conditions of the lower esophagus and the stomach wall.
The compound contrast agent is orally taken and used for checking gastroesophageal reflux in an ultrasonic contrast mode. The composite contrast agent (suspension) has stable performance, the emptying time is obviously slower than that of intravascular imaging, the imaging is clear in an ultrasonic imaging mode, only the lower esophagus and the stomach which need to be observed are displayed, the surrounding tissues are filtered for imaging, the gastroesophageal reflux condition can be more intuitively and clearly displayed, and no side effect is caused.
The detection time is 5-10 minutes after the medicine is taken, and much time is saved compared with the pressure measurement in 24 hours and the painless gastroscope; the detection result is stable and accurate, the experience of the patient is good, and the pain is avoided.
Drawings
FIG. 1 is a graph showing a mixed contrast medium for reflux combined hiatal hernia in test example 3 of the present invention
FIG. 2 is a diagram of a mixed contrast medium of test example 1 of the present invention
FIG. 3 is a diagram showing the spectrum of pw in experiment two of the present invention
Detailed Description
The present invention will be further explained with reference to the following embodiments, wherein sononovine used in the embodiments is sulfur hexafluoride micro-bubble for injection, gastric contrast agent is instant gastrointestinal ultrasound contrast agent of toshiba pharmaceutical products limited, lazhou, and dynamic real-time observation equipment is a high-end comprehensive color ultrasound machine with ultrasound contrast function:
example 1
A sononovacin compound contrast agent is prepared by dissolving sononovacin (sulfur hexafluoride microbubble for injection) 59mg and normal saline 5ml to obtain sononovacin solution, adding sononovacin solution 0.5ml into boiling water 500ml, and stirring. After cooling, the medicine is taken orally and then is tested for gastroesophageal reflux disease.
Boiling water at 97 deg.C, and optionally purified water.
The suspension has stable performance, the emptying time is obviously slower than that of intravascular imaging, the imaging is clear in an ultrasonic imaging mode, only the lower esophagus and the stomach which need to be observed are displayed, the surrounding tissues are filtered for imaging, the gastroesophageal reflux condition can be more intuitively and clearly displayed, and no side effect is caused. And the real-time dynamic image storage in the checking process is more convenient for post-processing and analysis.
The composite contrast agent is used to check gastroesophageal reflux in an ultrasound contrast mode after the oral route.
The sononovacin compound contrast agent is colorless, tasteless, nontoxic and free of side effects, the contrast agent is not metabolized by a liver and kidney circulation system, the time of microbubbles existing in the stomach is obviously prolonged compared with intravascular ultrasound contrast, and the gastroesophageal reflux condition can be observed conveniently. The scattering effect of the microbubbles after the vibration is more favorable for observing the flowing condition of the contrast agent in the stomach and the esophagus, and the specificity, the sensitivity and the diagnosis coincidence rate of the ultrasonic diagnosis of the gastroesophageal reflux disease are improved.
Example 2
The application of sononovine in preparing the composite contrast agent for detecting gastroesophageal reflux disease adopts an oral administration mode.
59mg of sononovacin and 5ml of normal saline are completely dissolved to form sononovacin solution, then 3ml of sononovacin solution is taken and added into 600ml of boiling water, and the mixture is stirred evenly. After cooling, the medicine is taken orally and then is tested for gastroesophageal reflux disease.
Boiling water at 100 deg.C, and optionally purified water.
Example 3
The application of sononovine in preparing the composite contrast agent for detecting gastroesophageal reflux disease adopts an oral administration mode.
59mg of sononovacin and 5ml of normal saline are completely dissolved to form sononovacin solution, 2.5ml of sononovacin solution is taken and added into 500ml of boiling water, and the mixture is stirred uniformly. After cooling, the medicine is taken orally and then is tested for gastroesophageal reflux disease.
Boiling water at 99 deg.C, and optionally purified water.
Example 4
The application of sononovine in preparing the composite contrast agent for detecting gastroesophageal reflux disease adopts an oral administration mode.
Sononovacin 59mg and physiological saline 5ml are dissolved to form sononovacin solution completely. Mixing and dissolving the gastrointestinal development aid 50g and boiling water 500ml uniformly, cooling to 40 ℃, adding sononovalr solution 2.5ml, and stirring uniformly.
After cooling, the medicine is taken orally and then is tested for gastroesophageal reflux disease. Adding the prepared Sonoweiwei solution when the water temperature or the prepared gastric development aid is cooled to the required temperature, and taking orally when the examination is started.
Boiling water at 95 deg.C, and optionally purified water.
The gastrointestinal development aid is firstly mixed with water and dissolved uniformly, and then the mixture is cooled to 40 ℃ and added with the sononovalr solution and stirred uniformly. The gastrointestinal development aid is added, so that the gastroesophageal reflux condition can be visually and clearly displayed, the emptying time in the stomach is prolonged, and repeated observation is facilitated repeatedly; meanwhile, the condition of the stomach can be clearly observed under a conventional ultrasonic mode. Overcomes the problems of relatively short retention time in the stomach, rapid emptying and difficult repeated observation.
Example 5
The application of sononovine in preparing the composite contrast agent for detecting gastroesophageal reflux disease adopts an oral administration mode.
Sononovacin 59mg and physiological saline 5ml are dissolved to form sononovacin solution completely. Mixing and dissolving the gastrointestinal development aid 50g and boiling water 500ml uniformly, cooling to 38 ℃, adding sononovalr solution 2ml, and stirring uniformly.
After cooling, the medicine is taken orally and then is tested for gastroesophageal reflux disease.
Boiling water at 98 deg.C, and optionally purified water.
Example 6
The application of sononovine in preparing the composite contrast agent for detecting gastroesophageal reflux disease adopts an oral administration mode.
Sononovacin 59mg and physiological saline 5ml are dissolved to form sononovacin solution completely. Mixing and dissolving gastrointestinal development aid 50g and boiling water 300ml uniformly, cooling to 37 deg.C, adding Sonoweiwei solution 1ml, and stirring uniformly.
After cooling, the medicine is taken orally and then is tested for gastroesophageal reflux disease.
Boiling water at 100 deg.C, and optionally purified water.
Example 7
The application of sononovine in preparing the composite contrast agent for detecting gastroesophageal reflux disease adopts an oral administration mode.
Sononovacin 59mg and physiological saline 5ml are dissolved to form sononovacin solution completely. Mixing and dissolving the gastrointestinal development aid 50g and boiling water 600ml uniformly, cooling to 39 ℃, adding sononovalr solution 1.5ml, and stirring uniformly.
After cooling, the medicine is taken orally and then is tested for gastroesophageal reflux disease.
Boiling water at 100 deg.C, and optionally purified water.
Example 8
A method of detecting gastroesophageal reflux disease comprising the steps of:
(1) the Sonoweiwei (sulfur hexafluoride microvesicle for injection) contrast agent is mixed according to the requirements of medicine use instruction and detection dosage; the dosage ratio can be adjusted according to the body fat ratio of the patient.
(2) Orally administering the cooled sononovacin complex contrast agent to a patient;
(3) the patient can be in a horizontal position or a right-side horizontal position according to the requirement of the body position to be checked;
(4) dynamically observing, recording and storing images in real time; the instrument for real-time observation is a high-end comprehensive color ultrasonic machine with an ultrasonic contrast function.
(5) Observing for 5-10 minutes, if the reflux times are more than or equal to 3 times in the observation process, the gastroesophageal reflux can be diagnosed by the reflux time being more than or equal to 1s, or the reflux is generated in the observation process, but the reflux times and the reflux time are less than the standard, the physiological reflux can be diagnosed, namely, the gastroesophageal reflux disease does not exist.
Example 9
A method of detecting gastroesophageal reflux disease comprising the steps of:
(1) the Sonoweiwei (sulfur hexafluoride microvesicle for injection) contrast agent is mixed according to the requirements of medicine use instruction and detection dosage; the dosage ratio can be adjusted according to the body fat ratio of the patient.
(2) Blending the gastric contrast medium, namely adding the sononovacin solution into the gastric contrast medium solution to form a composite contrast medium;
(3) orally administering the cooled sononovacin complex contrast agent to a patient;
(3) the patient can check the requirements of body position, namely a horizontal position and a right-side horizontal position;
(4) dynamically observing, recording and storing images in real time;
(5) the patient can be advised to increase the abdominal pressure in the observation process;
the method for checking body position and increasing abdominal pressure in the checking process is easier to be used for gastroesophageal reflux, and real-time dynamic image storage is more convenient for post-processing and analysis.
(6) Observing for 5-10 minutes, if the reflux times are more than or equal to 3 times in the observation process, the gastroesophageal reflux can be diagnosed by the reflux time being more than or equal to 1s, or the reflux is generated in the observation process, but the reflux times and the reflux time are less than the standard, the physiological reflux can be diagnosed, namely, the gastroesophageal reflux disease does not exist.
The following experimental examples are oral administration of the sononov compound contrast agent of the present invention, and the dynamic real-time observation device is a high-end integrated color ultrasound machine with an ultrasound contrast function, and the models are philips EPQ5 and philips IU22, and the color ultrasound machine has a function of storing dynamic images. Increasing abdominal pressure is the medical Vasalva test (meaning that during the examination, the examiner occludes air after deep inspiration). And dynamically observing in real time in the detection process to count the reflux times.
Test example 1
Female, 53 years old, radiating pain in shoulders, poststernal and subxiphoid pain 2 years +, gastroscopic diagnosis: reflux esophagitis (LA-C grade). Ultrasonic diagnosis of gastroesophageal reflux: after the sononowei compound contrast medium (the sononowei solution is 2.0ml and 500ml of the gastric contrast medium solution) is orally taken, the cardia is continuously opened when ultrasonic observation is carried out at 5m15s-5m45s in a right lateral decubitus position, and the sononowei compound contrast medium in the stomach continuously flows back to the abdominal esophagus through the cardia. Ultrasonic diagnosis: gastroesophageal reflux. Performing endoscopic diagnosis: reflux esophagitis (grade LA-B), as shown in figure 2.
Test example 2
The patient female, 48 years old, observed 10 minutes after simple oral administration of the gastric contrast medium solution, did not find gastroesophageal reflux.
After the same patient was orally administered sononovacin complex contrast agent (sononovacin 1.0ml +300ml gastric contrast agent solution), ultrasonic examination was performed in the right lateral decubitus: cardia opening is observed at 3m15s, 3m45s and 4m20s respectively, and the intragastric sononovacin compound contrast agent flows back to the esophagus of the abdominal part through the cardia. Ultrasonic diagnosis of gastroesophageal reflux. PH detection at 24 hours suggested: pathological acid reversal (mild).
Test example 3
The patient male, 82 years old, after taking the compound sononovacin contrast agent (0.4 ml +500ml stomach contrast agent solution) orally, the esophageal hiatus is enlarged (2.0-2.4cm) in the right lateral decubitus and the flat decubitus, abdominal segment esophagus disappears in the examination process, the fundal hernia enters above diaphragm, the cystic hernia echo of the compound sononovacin contrast agent with the size of about 4.6x5.4cm can be seen on the diaphragm, and the detection is determined as esophageal hiatus hernia combined with gastroesophageal reflux. And (4) CT prompting: hiatal hernia. As in fig. 1.
Test example 4
Patients male, 38 years old, after oral administration of sononovyl complex contrast medium ("sononovyl solution 3.0ml +600ml gastric contrast medium solution"), ultrasound examination in right and horizontal positions: cardia opening is observed when the contrast medium is 2m36s-2m39s, 3m20s and 4m35-4m40s respectively, and the intragastric sononovacin compound contrast medium flows back to the esophagus of the abdominal part through the cardia. Ultrasonic diagnosis of gastroesophageal reflux. PH detection at 24 hours suggested: pathological acid reversal (mild).
Test example 5
Patient women, 42 years old, after oral administration of sononovyi complex contrast medium ("sononovyi solution 2.0ml +500ml gastric contrast medium solution"), ultrasound examination in right lateral decubitus: cardia opening is observed at 3m36s, 4m27s, 4m45s and 5m58s respectively, and the intragastric sononovacin compound contrast agent flows back to the abdominal esophagus through the cardia. Ultrasonic diagnosis of gastroesophageal reflux. And (3) clinical diagnosis: gastroesophageal reflux.
Test example 6
Patient women, 51 years old, after oral administration of sononovyi complex contrast medium ("sononovyi solution 1.0ml +300ml gastric contrast medium solution"), ultrasound examination in right lateral decubitus: cardia opening was observed at 2m49s, 3m20s, 3m56s, 4m32s, 5m15s, and 5m29s, respectively, and the intragastric sononovacin complex contrast agent flowed backward through the cardia into the abdominal esophagus. Ultrasonic diagnosis of gastroesophageal reflux. Performing endoscopic diagnosis: 3 reflux 3 esophagitis 3 ( 3 LA 3- 3 A 3 grade 3) 3. 3
Test example 7
Patients male, 40 years old, after oral administration of sononovyl complex contrast medium ("sononovyl solution 2.0ml +600ml gastric contrast medium solution"), ultrasound examination in right lateral decubitus: cardia opening was observed at 4m59s and 5m48s, respectively, and the sononovacin complex contrast agent in the stomach flowed back through the cardia into the abdominal esophagus. Ultrasonic diagnosis, physiological gastroesophageal reflux. PH detection at 24 hours suggested: normal physiological acid reversal.
Test No.)
Two groups of experiments are set, 66 experiments are respectively carried out, and a control group uses the gastric development aid (named as Tianxia brand) according to the use instructions; the test group is the sononovacin compound contrast agent (sononovacin (sulfur hexafluoride) + gastric development aid) of the invention, which is orally taken, dynamically observed in real time, recorded and stored, and observed for 5-10 minutes. The results are given in table 1 below:
TABLE 166 cases of contrast agent for gastric contrast medium and the method of ultrasonic contrast examination with mixed solution of the present invention
Note: chi shape2＝4.5，P＜0.05
As can be seen from the above, the composite contrast agent of the invention has better effect in detection, and has high stability and accuracy compared with the traditional method.
Test No. two
The patient, female, is 51 years old, clinically burns heart, acid regurgitation, hiccup and belching for 10 years +, and has unknown treatment. Gastroscope detection: 3 reflux 3 esophagitis 3 ( 3 LA 3- 3 a 3 grade 3) 3, 3 chronic 3 non 3- 3 atrophic 3 gastritis 3. 3 Ultrasonic diagnosis: gastroesophageal reflux.
As in fig. 3, PW is shown to check for regurgitation, and by this measure the time of regurgitation and the rate of regurgitation; the reflux time of one reflux is 2318ms, and the speed is 40 cm/s.
The composite contrast agent can eliminate gas in the stomach and the esophagus and filter the surrounding tissues for developing in an ultrasonic contrast mode, can better display the lower esophageal segment and the stomach pathological changes, and is beneficial to observing the conditions of the lower esophageal segment and the stomach wall carefully for a long time due to slow excretion time in the stomach. The detection time is short, the detection is rapid, the cost is low, the efficiency is high, the detection accuracy is high, and the composite contrast agent has no side effect. And the construction of a gastroesophageal reflux ultrasonic contrast evaluation system in the Chinese clinical test registration center is also added.
While the foregoing shows and describes the fundamental principles and principal features of the invention, together with the advantages thereof, the foregoing embodiments and description are illustrative only of the principles of the invention, and various changes and modifications can be made therein without departing from the spirit and scope of the invention, which will fall within the scope of the invention as claimed. The scope of the invention is defined by the appended claims and equivalents thereof.
Claims (10)
1. A sononovine compound contrast agent is characterized in that: comprises 0.5-3ml of sononovacin solution and 300-600ml of water, wherein the sononovacin solution is prepared by dissolving 59mg of sononovacin in 5ml of normal saline.
2. The sononovammal complex contrast medium of claim 1, wherein: 2.5ml of sononovacin solution and 500-600ml of water; 500ml of water is used in the optimized scheme.
3. The sononovammal complex contrast medium of claim 1, wherein: the water is boiling water at 95-100 deg.C.
4. The sononovammal complex contrast agent according to claim 1 or 3, wherein: the composite contrast agent also comprises 50g of gastrointestinal development aid.
5. The method for preparing sononovacin complex contrast agent according to claim 4, wherein: sequentially comprises a sononovacin solution blending step and a composite contrast agent blending step; or sequentially comprises a sononovalvine solution mixing step, a stomach development assistant mixing step and a composite contrast agent mixing step.
6. The application of the sononovacin compound contrast agent is characterized in that: application of sononovine in preparation of composite contrast agents.
7. The use of sononovacin complex contrast medium as claimed in claim 6, wherein: application of sononovine in preparation of composite contrast agent for detecting gastroesophageal reflux disease.
8. The use of sononovacin complex contrast medium as claimed in claim 7, wherein: the application mode in detecting the gastroesophageal reflux disease is an oral mode.
9. The use of sononovacin complex contrast medium as claimed in claim 8, wherein: the specific steps of the application in detecting the gastroesophageal reflux disease are as follows:
(1) mixing with Sonoweiwei compound contrast medium;
(2) orally administering sononovacin complex contrast agent to the patient;
(3) according to the requirement of the checking body position, the patient is in a horizontal position or/and a right side position;
(4) dynamically observing and recording a concurrent image in real time;
(5) observing for 5-10min, if the reflux times are more than or equal to 3 times in the process, the reflux time is more than or equal to 1s, the gastroesophageal reflux can be diagnosed, or the reflux exists in the process, but the reflux times and the reflux time are less than the standard, the physiological reflux can be diagnosed, namely, the gastroesophageal reflux disease does not exist.
10. The use of sononovacin complex contrast medium as claimed in claim 9, wherein: and a step of increasing abdominal pressure is also carried out between the step (4) and the step (5).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911165846.XA CN111166897A (en) | 2019-11-25 | 2019-11-25 | Sonoweiwei compound contrast agent and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911165846.XA CN111166897A (en) | 2019-11-25 | 2019-11-25 | Sonoweiwei compound contrast agent and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111166897A true CN111166897A (en) | 2020-05-19 |
Family
ID=70617676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911165846.XA Withdrawn CN111166897A (en) | 2019-11-25 | 2019-11-25 | Sonoweiwei compound contrast agent and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111166897A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100012293A (en) * | 2008-07-28 | 2010-02-08 | 주식회사 리제론 | Process for preparing phospholipids using supercritical fluids |
| CN109758591A (en) * | 2018-12-18 | 2019-05-17 | 深圳先进技术研究院 | The preparation method and application of planktonic algae containing pseudo- ghost |
-
2019
- 2019-11-25 CN CN201911165846.XA patent/CN111166897A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100012293A (en) * | 2008-07-28 | 2010-02-08 | 주식회사 리제론 | Process for preparing phospholipids using supercritical fluids |
| CN109758591A (en) * | 2018-12-18 | 2019-05-17 | 深圳先进技术研究院 | The preparation method and application of planktonic algae containing pseudo- ghost |
Non-Patent Citations (3)
| Title |
|---|
| 吴蠡荪 等主编: "《新编临床辅助检查指南 第3版》", 31 December 2017, 中国医药科技出版社 * |
| 彭利 等: "口服声诺维微泡超声增强剂与胃助显剂混合液对胃食管反流病的诊断效能", 《西部医学》 * |
| 彭利: "胃充盈超声造影与内镜检查对胃食管反流病的诊断价值", 《西部医学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chew et al. | Anal fistula: Levovist®-enhanced endoanal ultrasound: A pilot study | |
| Kato et al. | Ultrasonographic and endoscopic ultrasonographic angiography in pancreatic mass lesions | |
| Mitake et al. | Endoscopic ultrasonography in the diagnosis of depth invasion and lymph node metastasis of carcinoma of the papilla of Vater. | |
| Ohto et al. | Real-time sonography of the pancreatic duct: application to percutaneous pancreatic ductography | |
| Folvik et al. | Hydrosonography of the small intestine: comparison with radiologic barium study | |
| Iqbal et al. | Diagnostic efficiency of multidetector computed tomography in the evaluation of clinically equivocal cases of acute appendicitis with surgical correlation | |
| JPH06116170A (en) | X-ray contrast medium for examining intestine crassum and intestine tenue | |
| Gordon et al. | Endosonographic evaluation of mural abnormalities of the upper gastrointestinal tract | |
| Sivak et al. | Endoscopic ultrasonography in the differential diagnosis of pancreatic disease: a preliminary report | |
| Andrzejewska et al. | The role of intestinal ultrasound in diagnostics of bowel diseases | |
| CN101698105B (en) | Gastrointestinal tract contrast medium | |
| CN111166897A (en) | Sonoweiwei compound contrast agent and application | |
| Gaschen et al. | Endoscopic ultrasound instrumentation, applications in humans, and potential veterinary applications | |
| Xie et al. | Magnetically guided capsule endoscopy in pediatric patients with abdominal pain | |
| Zhu et al. | Contrast‐Enhanced Ultrasound Diagnosed a Pyriform Sinus Fistula That Failed to Be Diagnosed by a Barium Swallow Examination: Case Report and Review of Choices for the Imaging Examination. | |
| Fireman et al. | Small bowel capsule endoscopy: have we conquered the last frontier | |
| Wang et al. | Contrast-enhanced ultrasound using SonoVue mixed with oral gastrointestinal contrast agent to evaluate esophageal hiatal hernia: Report of three cases and a literature review | |
| Mohan et al. | One year experience of OMOM capsule endoscopy for suspected small intestine lesions | |
| Clayton | Focus on Diagnosis: Pediatric Abdominal Imaging | |
| Wen et al. | Detection of tumor vascularity in hepatocellular carcinoma with contrast-enhanced dynamic flow imaging: comparison with contrast-enhanced power Doppler imaging | |
| CN104189926A (en) | Quick developer for gastric B ultrasound | |
| Qi et al. | Application of endoscopic ultrasound image analysis in the treatment of digestive tract diseases and nursing | |
| Grüßner et al. | Significance of ultrasound for the diagnosis of hypertrophic pyloric stenosis | |
| Maharjan et al. | A case of significant weight loss and severe malnutrition caused by achalasia | |
| Kang et al. | Evaluation of a dual-purpose contrast medium for radiography and ultrasonography of the small intestine in dogs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200519 |
|
| WW01 | Invention patent application withdrawn after publication |